<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03054285</url>
  </required_header>
  <id_info>
    <org_study_id>209136</org_study_id>
    <nct_id>NCT03054285</nct_id>
  </id_info>
  <brief_title>Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?</brief_title>
  <official_title>Does Short-Term Anti-Seizure Prophylaxis After Traumatic Brain Injury Decrease Seizure Rates?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loyola University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to prospectively assess in randomized fashion whether
      short term anti-seizure prophylaxis in traumatic brain injured patients decreases the
      incidence of seizures in the early post-injury period. A secondary objective is to evaluate
      whether there are differences in mortality, hospital length of stay, functional outcome at
      hospital discharge, hospital cost, discharge status (home, rehabilitation facility, etc.) for
      patients who receive and do not receive anti-seizure prophylaxis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The efficacy of anti-seizure prophylaxis in head injury patients remains controversial.
      Current recommendations for the use of anti-seizure prophylaxis are based upon a single
      institution study that has not been reproduced with other studies contradicting their
      conclusions. The proposed study will be a randomized prospective study at Loyola University
      Medical Center to assess the efficacy of anti-seizure prophylaxis in patients who have
      suffered traumatic brain injury (TBI). Patients with suspected TBI will undergo computed
      tomographic (CT) scan of the head. Following identification of TBI on CT scan, patients will
      be randomized to one of two study groups. Patients will be randomized to receive a seven-day
      course of anti-seizure prophylaxis with levetiracetam (UCB Pharma Inc.; Keppra) or randomized
      to a study group that will not receive anti-seizure prophylaxis. Patients will be consented
      prior to entry in the study. Patients will be followed for a total of seven days post injury
      for clinical signs of seizure activity. Additionally, patients will be assessed at one month
      post injury for clinical signs of seizure activity.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">April 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The intervention study model is a randomized block design using a 1:1 allocation scheme</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seizures (count of seizures)</measure>
    <time_frame>30 days</time_frame>
    <description>For all patients, the count of seizures will be recorded and compared between the two arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>30 days</time_frame>
    <description>For all patients, days from head injury to death or last follow-up will be recorded and compared between the two arms.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2300</enrollment>
  <condition>Seizures</condition>
  <condition>Traumatic Brain Injury</condition>
  <arm_group>
    <arm_group_label>No seizure prophylaxis</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Participants randomized to this arm will not receive anti-seizure prophylaxis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seizure Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomized to this arm will receive the anti-seizure prophylaxis drug Levetiracetam for seven days post traumatic brain injury.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levetiracetam</intervention_name>
    <description>Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury</description>
    <arm_group_label>Seizure Prophylaxis</arm_group_label>
    <other_name>Keppra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have suffered intracranial injury identified by CT Scan

        Exclusion Criteria:

          -  Age less than 18

          -  Pregnant patients

          -  Death in ED

          -  Seizure history or use of antiepileptic medication prior to admission

          -  Contraindication to study drug

          -  Any post-injury seizures prior to randomization
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard P Gonzalez, MD</last_name>
    <phone>708-327-2072</phone>
    <email>richard.gonzalez@lumc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Anstadt, MD</last_name>
    <phone>708-327.2072</phone>
    <email>manstadt@lumc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Gonzalez, MD</last_name>
      <phone>708-327-2072</phone>
      <email>richard.gonzalez@lumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michael Anstadt, MD</last_name>
      <phone>708-327-2706</phone>
      <email>manstadt@lumc.edu</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pitk√§nen A, Immonen R. Epilepsy related to traumatic brain injury. Neurotherapeutics. 2014 Apr;11(2):286-96. doi: 10.1007/s13311-014-0260-7. Review.</citation>
    <PMID>24554454</PMID>
  </reference>
  <reference>
    <citation>Torbic H, Forni AA, Anger KE, Degrado JR, Greenwood BC. Antiepileptics for seizure prophylaxis after traumatic brain injury. Am J Health Syst Pharm. 2013 Dec 1;70(23):2064, 2067. doi: 10.2146/ajhp130439.</citation>
    <PMID>24249751</PMID>
  </reference>
  <reference>
    <citation>Cranley MR, Craner M, McGilloway E. Antiepileptic prophylaxis following severe traumatic brain injury within a military cohort. J R Army Med Corps. 2016 Apr;162(2):109-14. doi: 10.1136/jramc-2014-000392. Epub 2015 Feb 24.</citation>
    <PMID>25712562</PMID>
  </reference>
  <reference>
    <citation>Temkin NR, Dikmen SS, Wilensky AJ, Keihm J, Chabal S, Winn HR. A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures. N Engl J Med. 1990 Aug 23;323(8):497-502.</citation>
    <PMID>2115976</PMID>
  </reference>
  <reference>
    <citation>Young B, Rapp RP, Norton JA, Haack D, Walsh JW. Failure of prophylactically administered phenytoin to prevent post-traumatic seizures in children. Childs Brain. 1983;10(3):185-92.</citation>
    <PMID>6409521</PMID>
  </reference>
  <reference>
    <citation>Bhullar IS, Johnson D, Paul JP, Kerwin AJ, Tepas JJ 3rd, Frykberg ER. More harm than good: antiseizure prophylaxis after traumatic brain injury does not decrease seizure rates but may inhibit functional recovery. J Trauma Acute Care Surg. 2014 Jan;76(1):54-60; discussion 60-1. doi: 10.1097/TA.0b013e3182aafd15.</citation>
    <PMID>24368357</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>February 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Loyola University</investigator_affiliation>
    <investigator_full_name>Richard Gonzalez</investigator_full_name>
    <investigator_title>Director of Trauma, Critical Care, Burns and ACS</investigator_title>
  </responsible_party>
  <keyword>Seizures</keyword>
  <keyword>Traumatic Brain Injury</keyword>
  <keyword>Prophylaxis</keyword>
  <keyword>Levetiracetam</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
    <mesh_term>Brain Injuries, Traumatic</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Etiracetam</mesh_term>
    <mesh_term>Piracetam</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

